Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HitGen and Cambridge Molecular Form Alliance to Source Ligands for Targets

publication date: Nov 5, 2021

Chengdu's HitGen formed a strategic alliance with Cambridge Molecular of the UK to offer CM's DeepDELve 2 pipeline that identifies potential ligands for drug targets. HitGen's drug discovery platform for small molecules and nucleic acid drugs is based on DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. It currently contains over 1 trillion novel drug-like small molecules and macrocyclic compounds. CM's DeepDELve 2 analyzes selected DEL candidates to identify ligands that are appropriate and commercially available. More details...

Stock Symbol: (SHA: 688222)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.